Latest Licensing Agreements News

InFocus Group Holdings has launched a dedicated iGaming business unit, aiming to capitalize on the booming $95 billion online gaming industry with key contracts and digital asset integration.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.

X2M Connect has secured a significant contract to digitise water meters for 6,750 Seoul households, marking a key step in the city's ambitious A$240 million smart metering initiative.

Starpharma has entered a significant collaboration with Genentech to develop dendrimer-drug conjugates for oncology, securing an upfront payment and potential milestone earnings exceeding half a billion dollars.

Starpharma has entered a landmark collaboration with Genentech to develop innovative cancer therapies using its proprietary DEP® platform, securing $5.5 million upfront and potential milestones exceeding $560 million.

LTR Pharma has acquired a one-third equity stake in LevOmega Pty Ltd at no cost to shareholders, positioning itself in the growing pharmaceutical-grade omega-3 sector. This strategic move complements LTR’s existing intranasal pharmaceutical portfolio and aligns with its innovation-driven growth strategy.

Wellnex Life Limited has expanded its financing with a new A$2.5 million loan facility, enhancing its financial flexibility to support ongoing business growth and settle long-term obligations.

PARKD Limited has clinched exclusive national rights to prefabricate key modular building components from Fielders, positioning itself to capitalize on booming construction sectors like data centres and self-storage across Australia.

Jumbo Interactive has inked a five-year SaaS agreement to power RSL Queensland’s Dream Home Art Union lottery, Australia’s largest prize home lottery. This deal marks a strategic shift from reseller to platform partner, reinforcing Jumbo’s leadership in the charity lottery sector.

Livium Ltd has inked a term sheet with the University of Melbourne to exclusively commercialise innovative microwave technology for rare earth elements extraction, promising high recovery rates and major energy savings.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.